TITLE

Telaprevir Film-Coated Tablets (Incivek)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
June 2011
SOURCE
Internal Medicine Alert;6/29/2011, Vol. 33 Issue 12, p93
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents a randomized clinical study which evaluates the safety and efficacy of the protease inhibitor Telaprevir which is marketed as Incivek drug for the treatment of genotype 1 chronic hepatitis C.
ACCESSION #
63484718

 

Related Articles

  • New HCV treatments mean more patients to treat in France.  // PharmacoEconomics & Outcomes News;10/29/2011, Issue 640, p7 

    The article reports on a study which predicts that with the new combination therapy of peginterferon plus ribavirin and a protease inhibitor (PI), there will be a greater number of patients in France with genotype 1 (G1) hepatitis C virus (HCV) who will be treated than those receiving...

  • NICE recommends simeprevir for genotype 1 hepatitis C.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p39 

    The article reports on the recommendation of the British public body National Institute of Clinical Excellence (NICE) regarding simeprevir drug, in combination with peginterferon α and ribavirin, as a treatment option for genotype 1 chronic hepatitis C in adult patients.

  • Long-term efficacy of ribavirin plus interferon alfa for chronic hepatitis C. D.G.; Greenwald, David // Cortlandt Forum;04/25/97, Vol. 10 Issue 4, p32 

    Looks into a study by M.Y. Lai, J.H. Kao, et al published in `Gastroenterology' which evaluated interferon-alpha alone and combined with ribavirin in the treatment of chronic hepatitis C. Percentage of success of both protocols; Side effects; Low levels of success of interferon-alpha;...

  • New drugs.  // Australian Prescriber;Jun2012, Vol. 35 Issue 3, p102 

    The article offers information on the boceprevir drug used in the treatment of hepatitis C disease. It states that boceprevir is a protease inhibitor which when added to peginterferon alfa and ribavirin significantly improves the sustained virological response in patients with chronic hepatitis...

  • Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. D'Ambrosio, Roberta; Aghemo, Alessio; Colombo, Massimo // Biologics: Targets & Therapy;2012 Part 2, Vol. 6, p363 

    Telaprevir (TVR) is an orally available protease inhibitor of the hepatitis C virus that in association with pegylated interferon and ribavirin (PR) was shown to improve the rates of sustained virological response and potentially reduce treatment duration in adult patients with chronic hepatitis...

  • Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients. Goralczyk, Armin D.; Cameron, Silke; Amanzada, Ahmad // BMC Gastroenterology;2013, Vol. 13 Issue 1, p1 

    Background Telaprevir (TVR) has been approved for response-guided-therapy (RGT) of chronic hepatitis C (HCV) genotype-1-infection in treatment-naïve and -experienced patients. In RGTregimens patients that did not achieve extended rapid-virological-response (eRVR) within the first 4-12 weeks...

  • Boceprevir Capsules (Victrelisâ„¢). Elliott, William T.; Chan, James // Internal Medicine Alert;6/15/2011, Vol. 33 Issue 11, p84 

    The article evaluates the boceprevir capsule Victrelis, a protease inhibitor for the treatment of chronic hepatitis C (HCV) infections, from Merck & Co. Inc.

  • Enanta, Abbvie impress: 96 percent SVR12 in Phase III hepatitis C trial. Shaffer, Catherine // BioWorld Today;12/11/2013, Vol. 24 Issue 237, p1 

    The article reports on the 96 percent sustained virologic response achieved by Enanta Pharmaceuticals Inc. after 12 weeks of treatment for hepatitis C virus in its Phase III study of a regimen containing protease inhibitor ABT-450.

  • HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals. Cobb, Bryan; Pockros, Paul J; Vilchez, Regis A; Vierling, John M // American Journal of Gastroenterology;Apr2013, Vol. 108 Issue 4, p471 

    Recent regulatory approvals of the NS3/4A protease inhibitors boceprevir and telaprevir launched a new therapeutic era for hepatitis C virus (HCV) genotype 1 infection. Decisions to shorten, extend, or stop treatment with these direct-acting antiviral (DAA) regimens require accurate...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics